Alerta

BIOMARKER FOR DIAGNOSING SARCOPENIA AND SARCOPENIA DIAGNOSIS METHOD USING SAME

Resumen de: US20260338793A1

0000 A method for treating sarcopenia. The method involves measuring a protein or mRNA level of asporin, PADI2, adenosine 5′-monophosphoramidase HINT2, or HSDL2 in a biological sample isolated from a subject. The subject is diagnosed as having sarcopenia by comparing the protein or mRNA level of the subject measured with that of a control group, where the subject is diagnosed with sarcopenia when the protein or mRNA level of asporin or PADI2 in the subject is increased compared to that of the control group, or when the protein or mRNA level of adenosine 5′-monophosphoramidase HINT2 or HSDL2 in the subject is decreased compared to that of the control group. The subject diagnosed with sarcopenia is then treated.

METHODS AND COMPOSITIONS FOR CHRONIC INFLAMMATION USING COLCHICINE

Resumen de: US20260335261A1

Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.

A DETECTION METHOD

Resumen de: US20260338803A1

A method of detecting, predicting or monitoring the progress of amyloid angiopathy, ARIA (amyloid-related imaging abnormalities) or CAA (cerebral amyloid angiopathy) in an individual. The method comprises the step of: determining the presence or quantity of an Aβ protein fragment in a biological sample obtained from the individual, wherein the Aβ protein fragment is an Aβ1-40 or Aβx-34 fragment or a fragment of Aβ1-40.

COMPOSITIONS AND METHODS OF USE OF T CELLS IN IMMUNOTHERAPY

Resumen de: US20260337565A1

The present disclosure relates in some aspects to methods, cells, and compositions for preparing isolated engineered immune cells comprising T cell receptors (TCRs) capable of recognizing a disease-associated antigen. In some aspects, the immune cells are T cells for use in immunotherapy. Provided In an embodiment are T cell preparation methods, including isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are the isolated engineered T cells and compositions produced by the methods in the present disclosure. In some aspects, the methods prepare T cells for adoptive therapy. In an embodiment, the disease-associated antigen is a cancer-associated antigen.

METHOD FOR THE DETECTION OF DEMENTIA

Resumen de: US20260338802A1

The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.

エピジェネティックに修飾されたＤＮＡを捕捉する方法

Resumen de: WO2025083068A1

The present invention relates to methods for capturing nucleic acid sequences while keeping/preserving their epigenetic information, preferably for capturing certain regions of the genome, thereby enriching these regions, while maintaining it epigenetic information, with the same probability/efficiency, independently of whether one or more nucleotides are epigenetically modified. In particular, the present invention relates to a method comprising the steps of: (i) providing a plurality of nucleic acid molecules, wherein each of the nucleic acid molecules comprises two regions: a first region and a second region, wherein the base identities in the first and second region both provide, independently, information on the base identities in the corresponding loci of one or more original nucleic acid molecules, wherein the first and the second regions in each of the molecules provided in (i) comprise at least one nucleotide at a position corresponding to the same locus in a region of interest, wherein that locus in the region of interest is occupied by a nucleotide susceptible of being modified; wherein at least two of the nucleic acid molecules of the plurality of nucleic acid molecules may have a different nucleotide in the first region at least at one position corresponding to the same locus in the region of interest, wherein that locus in the region of interest is occupied by a nucleotide susceptible of being modified and wherein, in the second region, a position corresponding

ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF

Resumen de: US20260337258A1

Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.

パーキンソン病の早期バイオマーカー

Resumen de: WO2025078596A1

The present invention provides a non-invasive, ex vivo method for diagnosing, prognosing or monitoring Parkinson's disease (PD) in a subject, the method comprising determining the ratio of CD8 terminally- differentiated effector T cells (CD8 TEMRA) to CD8 central memory T cells (CD8 TCM) in a biological sample from the subject, and computer program products for carrying out the method. Also provided herein is a kit, in particular a kit for diagnosing, prognosing or monitoring PD, the kit comprising: (a) means specifically adapted for determining the ratio of CD8 TEMRA to CD8 TCM; and (b) optionally a reference for said ratio or means for establishing said reference, wherein said reference represents a known diagnosis or prognosis of PD, wherein (a) and optionally (b) are the only biological reagents present in said kit, and uses thereof.

Compositions, Kits, and Methods for Detecting Preclinical Alzheimer's Disease

Resumen de: AU2026253892A1

Abstract Compositions and kits for diagnosing and prognosing Alzheimer’s Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis- related molecules. Further compositions and kits employ panels of fluorophore- conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis- promoting agents and scavenger receptor agonists also appear. ct b s t r a c t c t

Blood-based assay for detecting tauopathy or amyloidogenic disease

Resumen de: AU2026249053A1

A method for detecting p217+tau in blood-based samples from a subject with high 5 sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The 10 amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the 15 assay. ct c t

PHARMACEUTICAL COMPOSITION COMPRISING HTRA ACTIVATOR AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DEGENERATIVE DISEASES, AND METHOD FOR SCREENING HTRA ACTIVITY MODULATOR

Resumen de: US20260335295A1

A compound represented by Formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof according to one aspect can be utilized as a preventive or therapeutic agent and the like for degenerative diseases, such as macular degeneration (AMD), cerebral amyloid angiopathy, hereditary stroke (CADASIL), and Alzheimer's disease (AD), in which HTRA1 activity deficiency is a factor in the aggravation of the diseases, and can be utilized as an adjuvant for efficiently and accurately performing screening of an HTRA activity modulator without temperature changes or the addition of substrates.

Biomarkers and uses thereof for diagnosing the silent phase of Alzheimer's disease

Resumen de: AU2026249014A1

A method of processing a biological sample in a microfluidic cartridge by generating a target analyte, binding the analyte to magnetic particles, actuating a plunger mechanism to pressurise reagent pouches and dispense reagents into interconnected reagent wells and a primary fluidic conduit to establish a fluidic circuit, and sequentially magnetically transporting the analyte-bound magnetic particles through the fluidic circuit from one reagent well to the next for assay processing. On-chip burst pouch106 Empty reaction chamber Rocker Cam 102 Filled reaction chamber Cam 102 Filled reaction chamber ct c t i l l e d r e a c t i o n c h a m b e r

BIOMARKERS OF THE INTEGRATED STRESS RESPONSE AND USES THEREOF

Resumen de: US20260337661A1

The present disclosure provides compositions and methods useful in modulating integrated stress response (ISR) and associated diseases or disorders and methods of identifying ISR modulators. The present disclosure also provides methods of treating neurodegenerative conditions and predicting beneficial effects and identifying suitable targets for treatment.

METHOD OF PROFILING THE ENERGETIC METABOLISM OF A POPULATION OF CELLS

Resumen de: US20260338764A1

The present invention relates to a method of profiling the energetic metabolism of a single cells. The inventors designed a method that rapidly and efficiently measures the protein synthesis level in single cells upon inhibition of the different energy producing pathways. The method developed by the inventors permits to acquire energetic metabolism profiles with single cell resolution in non-abundant cells ex-vivo and permits to decrease to a minimum manipulation time, incubations and cost of sample preparation. The method is particularly suitable for determining activation state of a cell, diagnosing inflammatory diseases, or predicting the response of a subject to immunotherapy treatment. In particular, the present invention relates to a method of profiling the energetic metabolism in single cells comprising measuring the protein synthesis level of the cells and contacting the cell with different inhibitors of metabolic pathways.

METHODS OF DETECTING CITRULLINATED PROTEINS

Resumen de: US20260338774A1

0000 Disclosed herein are methods of detecting citrullinated polypeptides and/or citrullinated peptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in various body fluids and/or tissues of individuals with autoimmune diseases, for example the synovium of subjects with rheumatoid arthritis. Further disclosed are methods of diagnosing, treating, selecting an individual for treatment of, and monitoring the treatment of autoimmune diseases, such as rheumatoid arthritis or hidradenitis suppurativa. Kits for use with the methods described herein are also provided.

COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS

Resumen de: US20260335402A1

The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.

METHODS FOR CELL-TYPE SPECIFIC PROFILING TO IDENTIFY DRUG TARGETS

Resumen de: US20260337666A1

The present invention provides methods of profiling gene and protein expression of a plurality of nuclei from a single cell type and comparing the profiles to determine variability among cell populations, samples from different subjects, and cells expressing a disease phenotype.

APOE GENOTYPING ASSAY

Resumen de: WO2026226519A1

Disclosed are methods of assessing apolipoprotein ("APOE") genotype based on multiple parallel assays. The assays allow for comparison of relative amounts of ApoE isoforms in patient samples to quickly determine relative isoform values without need of reference to calibrators. The methods further allow for diagnosis and/or risk assessment of a subject's likelihood of developing a neurodegenerative disease, such as Alzheimer's disease or suffering Amyloid-Related Imaging Abnormalities (ARIA) as a function of treatment for a neurodegenerative disease.

A MURINE MODEL FOR STUDYING A NEUROLOGICAL DISORDER

Resumen de: WO2026224399A1

A murine model for studying a neurological disorder A mouse model for monitoring disease progression of a neurological disorder, optionally when said disorder is associated with motor neuron degeneration in a subject. A method producing a model mouse comprising administering a non-transgenic mouse with circulatory extracellular vesicles isolated from the serum of a patient having a neurological disorder, preferably ALS. Also, a method for tracking the efficacy of a therapeutic agent for a neurological disorder comprising administering a therapeutic agent to the mouse model; measuring the one or more of markers for motor neuron activity and/or neuromuscular function; comparing the results of to those of an untreated mouse control.

検体希釈用液

Resumen de: JP2026174325A

0001 【課題】本発明は、免疫測定において高いＳ／Ｎ比をもたらす検体希釈用液の提供を目的の一つとする。 【解決手段】本発明は、検体中の検出対象タンパク質を検出するための免疫測定法において使用される検体希釈用液であって、無機塩を含有し、電気伝導度が１～３０ｍＳ／ｃｍである、検体希釈用液に関する。 【選択図】なし

SYSTEMS AND METHODS FOR ASSESSING EXPOSURE TO PESTICIDES

Resumen de: US20260338755A1

Rapid and accurate detection of personal exposure to or contamination with OP pesticides is critical to both research and clinical care for victims. However, this detection remains highly variable across commercially available assays, e.g., the Ellman method, and such assays may also not adequately detect low but clinically relevant levels of exposure biomarkers. Moreover, these assays are generally performed in the centralized laboratories, and is slow and expensive. These deficits translate into missed opportunities for the timely initiation of the most appropriate treatment and interventions for acutely or chronically poisoned victims. A simple, rapid, non-or minimally invasive biomonitoring tool for onsite sensitive and accurate detection of personal exposure to or contamination with OP pesticides is provided.

BLOCKING ITGB8 IN NEURODEGENERATIVE DISEASE

Resumen de: US20260337275A1

Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).

AMYLOID BETA DETECTION BY MASS SPECTROMETRY

Resumen de: EP4830807A2

0001 Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

PHOSPHO-TAU ANTIBODIES AND METHODS OF USE

Nº publicación: EP4830718A2 28/10/2026

Solicitante:

ALZPATH INC [US]
Alzpath, Inc.

Resumen de: EP4830718A2

0001 Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.